Newsletter July 2014

Updates are being expected for following Guidance documents on risk management of pharmaceuticals: ICH Q3 (Elemental impurities), ICH M7 (DNA reactive impurities in pharmaceuticals) and EMA (health based exposure limits in manufacture). More information on impact on the business and possible support by 2 Bridge is provided in attached Newsletter.

Download Newsletter